InventisBio is building up a pipeline of small molecule drug candidates targeting oncology and metabolic therapeutic areas. Currently three compounds, D-0120, D-0316, and D-0502 have been developed into clinical studies for the treatment of gout, non-small cell lung cancer (NSCLC) and breast cancer, respectively.
InventisBio actively pursues diversified collaborations with other companies, research institutes and universities to develop innovative drug products. Through scientific collaborations, joint clinical trials, and partnership in manufacturing and sales, we strive to accelerate commercialization of novel therapies in China and the rest of the world to address unmet medical needs, and to create a win-win situation. Currently, InventisBio is collaborating with other companies in the fields of oncology and immuno-oncology to develop clinical projects.
Copyright @2019 InventisBio (Shanghai) co., LTD31011502002476 Shanghai ICP